
    
      This is a non-interventional, single-cohort, prospective study of participants with moderate
      to severe CD. The study will review medical charts with prospective patient-reported outcome
      measures to provide real-world data to describe clinical outcomes and participant-reported
      symptom experience over 12 months following vedolizumab treatment initiation.

      The study will enroll approximately 140 participants. All participants will be enrolled in
      one observational group:

      â€¢ Vedolizumab

      This multicenter trial will be conducted in Canada. The overall duration of study will be
      approximately 24 months, including participant's enrolment period of 12 months and follow-up
      data collection period of 12 months.
    
  